Drug launch and Ph III trial watch list for top therapeutic areas

The therapeutics market is buzzing with activity, as several promising therapies are progressing to Phase III clinical trials and many more are awaiting commercial launches. As more complex specialty products are launched, the spending on personalized medicine will grow beyond oncology into areas such as infectious diseases (virology) and cardiology.

Market research firm Frost & Sullivan examined promising therapeutics for 2015 finding that oncology, cardiovascular, autoimmune/anti-inflammatories and infectious diseases will be the top areas of investments in 2015.

“In addition, pharmaceutical companies will be keen to invest in in-vitro diagnostics such as biomarkers; molecular, tissue, companion diagnostics; predisposition disease; and predictive testing,” said Frost & Sullivan Life Sciences global program director Jennifer Lazar, adding: “This is because drugs with companion diagnostics are expected to increase two- to three-fold over the next five years with increased focus on areas such as cardiology and inflammatory diseases.”